-
New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | Morningstar
ソース: Buzz FX / 18 9 2024 07:32:14 America/Chicago
[GlobeNewswire](/news/globe-newswire) New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment During year 5 of treatment wi
Read more...